Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Talazoparib (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors BioMarin Pharmaceutical; Pfizer
- 21 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 15 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Mar 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.